179 related articles for article (PubMed ID: 33753745)
1. The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data.
Modi ND; Tan JQE; Rowland A; Koczwara B; Abuhelwa AY; Kichenadasse G; McKinnon RA; Wiese MD; Sorich MJ; Hopkins AM
NPJ Breast Cancer; 2021 Mar; 7(1):30. PubMed ID: 33753745
[TBL] [Abstract][Full Text] [Related]
2. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
3. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data.
Modi ND; Tan JQE; Rowland A; Koczwara B; Kichenadasse G; McKinnon RA; Wiese MD; Sorich MJ; Hopkins AM
Front Oncol; 2020; 10():1130. PubMed ID: 32760671
[No Abstract] [Full Text] [Related]
5. Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
Gennari A; Amadori D; Scarpi E; Farolfi A; Paradiso A; Mangia A; Biglia N; Gianni L; Tienghi A; Rocca A; Maltoni R; Antonucci G; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2016 Aug; 159(1):79-86. PubMed ID: 27460638
[TBL] [Abstract][Full Text] [Related]
6. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
7. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C; Lederer B; Gade S; Vanoppen M; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Schneeweiss A; Paepke S; Jackisch C; Mehta K; Nekljudova V; Untch M; Neven P; von Minckwitz G; Loibl S
Breast Cancer Res Treat; 2015 Feb; 150(1):127-39. PubMed ID: 25677740
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
9. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
Krasniqi E; Pizzuti L; Barchiesi G; Sergi D; Carpano S; Botti C; Kayal R; Sanguineti G; Marchetti P; Botticelli A; Marinelli D; Gamucci T; Natoli C; Grassadonia A; Tinari N; Tomao S; Tonini G; Santini D; Michelotti A; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Cazzaniga M; Moscetti L; Fabbri A; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Garufi C; Di Stefano P; Mirabelli R; Veltri E; Paris I; Giotta F; Lorusso V; Landucci E; Ficorella C; Roselli M; Adamo V; Ricciardi G; Russo A; Valerio MR; Berardi R; Pistelli M; Cannita K; Zamagni C; Garrone O; Baldini E; Livi L; Meattini I; Del Medico P; Generali D; De Maria R; Risi E; Ciliberto G; Villa A; Sperduti I; Mazzotta M; Barba M; Giordano A; Vici P
J Cell Physiol; 2020 Nov; 235(11):7900-7910. PubMed ID: 31943171
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
11. Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer can reduce the Risk of Death in Obese Women: The EMILI Study.
Cortesi L; Sebastiani F; Iannone A; Marcheselli L; Venturelli M; Piombino C; Toss A; Federico M
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32605075
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.
Ligorio F; Zambelli L; Fucà G; Lobefaro R; Santamaria M; Zattarin E; de Braud F; Vernieri C
Ther Adv Med Oncol; 2022; 14():17588359221079123. PubMed ID: 35281350
[TBL] [Abstract][Full Text] [Related]
13. Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine.
Ang FLI; Rowland A; Modi ND; McKinnon RA; Sorich MJ; Hopkins AM
J Cancer; 2020; 11(11):3327-3333. PubMed ID: 32231738
[No Abstract] [Full Text] [Related]
14. The impact of overweight and obesity on breast cancer: data from Switzerland, so far a country little affected by the current global obesity epidemic.
Kann S; Schmid SM; Eichholzer M; Huang DJ; Amann E; Güth U
Gland Surg; 2014 Aug; 3(3):181-97. PubMed ID: 25207211
[TBL] [Abstract][Full Text] [Related]
15. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
Naik GS; Waikar SS; Johnson AEW; Buchbinder EI; Haq R; Hodi FS; Schoenfeld JD; Ott PA
J Immunother Cancer; 2019 Mar; 7(1):89. PubMed ID: 30922394
[TBL] [Abstract][Full Text] [Related]
16. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
18. Evidence and temporality of the obesity paradox in coronary bypass surgery: an analysis of cause-specific mortality.
Schwann TA; Ramia PS; Engoren MC; Bonnell MR; Goodwin M; Monroe I; Habib RH
Eur J Cardiothorac Surg; 2018 Nov; 54(5):896-903. PubMed ID: 29868854
[TBL] [Abstract][Full Text] [Related]
19. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
Neuhouser ML; Aragaki AK; Prentice RL; Manson JE; Chlebowski R; Carty CL; Ochs-Balcom HM; Thomson CA; Caan BJ; Tinker LF; Urrutia RP; Knudtson J; Anderson GL
JAMA Oncol; 2015 Aug; 1(5):611-21. PubMed ID: 26182172
[TBL] [Abstract][Full Text] [Related]
20. IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients.
Tong Y; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
Front Oncol; 2020; 10():550. PubMed ID: 32391265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
